Search results
With Duchenne decision ahead, FDA’s Marks pushes for speedy gene therapy approvals
BioPharma Dive via Yahoo Finance· 2 days agoBut the head of the FDA’s CBER office didn’t tip where the agency stands on potentially broadening...
Health Care: Republicans scrutinize FDA
Axios· 4 days agoThe FDA's drug approvals and oversight of lab-developed tests are again emerging as hot topics as House Republicans crank up oversight of the agency and...
FDA lifts hold on Larimar's Friedreich's Ataxia drug study By Investing.com
Investing.com· 5 days agoLarimar Therapeutics, Inc. (NASDAQ:LRMR), a biotechnology firm engaged in developing treatments for...
FDA grants Cartesian Therapeutics RMAT status for MG therapy By Investing.com
Investing.com· 4 days agoCartesian Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food...
ENDRA meets with FDA on liver device clinical trial design By Investing.com
Investing.com· 6 days agoFood and Drug Administration (FDA) regarding its TAEUS liver device. The meeting, which took place...
Earnings call: Vivos Therapeutics reports mixed Q1 results, aims for growth By Investing.com
Investing.com· 7 days agoVivos Therapeutics, a company specializing in the treatment of obstructive sleep apnea (OSA),...
Taylor Swift trained for ‘The Eras Tour’ in this posture-correcting sports bra that is on sale right...
The Patriot-News· 1 day agoTaylor Swift was pictured in a $185 posture-correcting sports bra from Forme while training for her...
House E&C hones in on accelerated approvals
Axios· 3 days agoThe FDA's drug approvals and oversight of lab-developed tests are again emerging as hot topics as House Republicans crank up oversight of the agency and...
Canaccord maintains Buy on Guardant Health stock, bullish on prospects By Investing.com
Investing.com· 4 days agoOn Wednesday, Canaccord Genuity (TSX:CF) maintained its Buy rating and $30.00 price target for...
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
InvestorPlace· 14 hours agoAs we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused...
